Japanese company profile · 9273

KOA SHOJI HOLDINGS CO.,LTD.

English company name recorded in Japan's EDINET filer data.

Original Japanese company name: コーア商事ホールディングス株式会社

Name follows the English name recorded in EDINET filer data. English company name source

FY2025 · fiscal year ended June 2026Latest filing date: 2026-09-18

What does this company do?

What does this company do?

In its FY2025 public filing, KOA SHOJI HOLDINGS CO.,LTD. reports Pharmaceutical sales, Pharmaceutical Manufacturing and Sales Business. The page shows business-level revenue and profit where the source disclosures support comparison.

KOA SHOJI HOLDINGS CO.,LTD.'s largest reported business by revenue in FY2025 was Pharmaceutical sales.

The business with the highest reported segment profit in FY2025 was Pharmaceutical sales.

FY2025 · fiscal year ended June 2026 · View original filing ↗ The source document may be in Japanese.

Reported company-wide figures

Company revenue
¥24.68B ↗
FY2025 · fiscal year ended June 2026
Operating profit
¥5.48B ↗
FY2025 · fiscal year ended June 2026
Comparable margin
22.2% ↗
FY2025 · fiscal year ended June 2026

JGAAP · Consolidated company-wide

Company profile

Company profile

Identity

Securities code
9273
EDINET code
E34071
Corporate number
6020001109452
Listing status
Listed
Industry (EDINET filer classification)
Pharmaceuticals

Location and fiscal year

Headquarters
神奈川県横浜市 · As filed in Japanese
Latest fiscal year
FY2025
Accounting standard
JGAAP
P16 data snapshot
2026-11-07

Company size

Employees (consolidated)
318 people (FY2025)
Employees (non-consolidated)
22 people (FY2025)
Capital stock
JPY 1.3 billion (FY2025)

Official information

Public information is organized and presented by P16. EDINET filer list (2026-11-07) Opens in a new tab · EDINET PDL 1.0 terms Opens in a new tab

Business structure

How does it make money?

Revenue leader and profit leader

Pharmaceutical sales

FY2025 · fiscal year ended June 2026 · Business Sales Operating profit
BusinessSalesShare of company salesOperating profitMargin
Pharmaceutical sales¥16.96B ↗63.7%63.7%Sales to external customers: ¥15.72B ↗¥3.31B ↗19.5%
Pharmaceutical Manufacturing and Sales Business¥8.96B ↗36.3%36.3%Sales to external customers: ¥8.96B ↗¥2.12B ↗23.7%

All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended June 2026. Revenue and profit are shown only where the filing and data support a comparison. “—” means a comparable amount was not disclosed. We compare sales to outside customers for each business and the company as a whole, using the same filing, fiscal year and scope. Reported business sales may include sales between businesses. We leave the share blank when the figures cannot be matched.

Company revenue

Company-wide trend

Company revenue

JGAAP · Consolidated
  1. FY202072.2¥17.82B
  2. FY202182.5¥20.35B
  3. FY202289.4¥22.05B
  4. FY202389.7¥22.13B
  5. FY202494.3¥23.27B
  6. FY2025100.0¥24.68B

Company operating profit

JGAAP · Consolidated
  1. FY202061.7¥3.38B
  2. FY202169.5¥3.81B
  3. FY202277.6¥4.25B
  4. FY202380.0¥4.38B
  5. FY202497.8¥5.36B
  6. FY2025100.0¥5.48B

Only reported years are shown. Missing years are left blank; accounting standards and scopes are kept in separate series.

Reported Sales by business over time

Reported Sales by business over time

Fiscal yearFY2021FY2022FY2023FY2024FY2025
Pharmaceutical sales¥14.72B¥16B¥15.46B¥15.93B¥16.96B
Pharmaceutical Manufacturing and Sales Business¥7.51B¥7.89B¥8.4B¥8.67B¥8.96B

All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.

What is growing?

What is growing?

Business revenue growth

This describes a reported period; it is not a forecast.

What has changed?

What has changed?

A five-year business-mix comparison is not shown because the available filings do not provide five comparable years on the same basis.

Source

Company profile

These scores summarize company characteristics using public filings. Comparison groups vary by measure. Higher is not always better.

  • Growth54
    Position among all companies with available values in the fixed reference data.FY2020→FY2025
  • Profitability96
    Position among all companies with available values in the fixed reference data.FY2025
  • Business concentration—
    No comparable data
  • Business change45
    Peer-position scoreFY2020→FY2025
  • Cash generation—
    No comparable data
  • Growth persistence79
    Peer-position scoreFY2020→FY2021, FY2021→FY2022, FY2022→FY2023, FY2023→FY2024, FY2024→FY2025

Next

Ask about this company

Source

Public filing

FY2025 · fiscal year ended June 2026

The source document may be in Japanese.

Filing ID: S100Z2Z6

View original filing ↗

根拠となる資料